– FRANCE, Paris – EUROAPI (EPA: EAPI) today announced the appointment of Mattias Perjos to its Board as an independent director, effective as of January 11, 2023.
“Throughout his career Mattias Perjos led successful healthcare activities and developed strong industrial skills with an international mindset. He will bring a wealth of experience that will be a strong addition to our Board,” said CEO, Karl Rotthier.
Concurrently, the company announced the resignation of Corinne Le Goff from her directorship on January 11, 2023.
About Mattias Perjos
Mattias Perjos is currently President and CEO of Getinge, a listed company on the Stockholm Stock Exchange, which he joined in 2017. He previously held the CEO position at Coesia IPS Division and Coesia International. Before that, Mattias Perjos was CEO of Flexlink and held other leading roles within the group he joined in 1998.
A Swedish citizen, Mattias Perjos holds a Master of Science in Industrial Engineering and Management.
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs worldwide. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization activities.
Taking action for health by enabling access to essential therapies inspires our 3,350 people every day. With solid research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.
For more information: https://www.euroapi.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
